儿科固体瘤的不断变化的负担:从1990年到2021年的全球分析
1Department of Pediatrics, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang Province, China.
Indian journal of cancer
|March 9, 2026
概括
儿科固体瘤在发病率和死亡率上显示出全球显著的差异. 有针对性的早期检测和治疗策略对于减少儿童癌症死亡率至关重要,特别是在资源较低的地区.
科学领域:
- 儿科瘤学 儿科瘤学
- 全球健康 全球健康
- 癌症流行病学 癌症流行病学
背景情况:
- 分析了七种主要的儿科固体瘤:脑癌,肝母细胞瘤,癌,恶性骨瘤 (MNBAC),神经母细胞瘤,视网膜母细胞瘤和软组织瘤.
- 数据涵盖1990年至2021年,重点关注0-19岁的个人.
研究的目的:
- 评估七种主要儿科固体瘤的全球发病率和死亡率趋势.
- 确定区域差异和与社会人口统计学因素的相关性.
主要方法:
- 利用了2021年全球疾病负担研究的数据.
- 分析按年龄,地区和社会人口统计指数 (SDI) 分层.
- 使用估计年度百分比变化 (EAPC) 评估的时间趋势.
主要成果:
- 2021年,全球发生了96,913例病例和42,869例死亡.
- 脑癌和MNBAC是最常见和最致命的;视网膜母细胞瘤发病率增加最多,而神经母细胞瘤死亡率上升.
- 报告指出,区域差异很大,东亚和撒哈拉以南非洲的负担最大;发病率因年龄组和SDI而异.
结论:
- 儿科固体瘤负担存在持续的全球和区域差异.
- 在低SDI地区的早期检测和针对高负担瘤的有针对性的策略对于降低死亡率至关重要.
相关概念视频
Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Pharmacokinetics in Pediatric Patients: Drug Distribution
407
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
407
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
595
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
595
Pharmacokinetics in Pediatric Patients: Drug Metabolism
306
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Drug Excretion
343
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343


